Chemotherapy ‘Has Limited Role’ After ICI Failure in Metastatic Melanoma

Source: Cancer Therapy Advisor, January 2022

In patients with metastatic melanoma whose disease progressed after immune checkpoint inhibitor (ICI) treatment, chemotherapy produces low response rates and short progression-free survival (PFS), according to a study published in the European Journal of Cancer.

The retrospective study included 463 patients with metastatic melanoma who were treated with various chemotherapy regimens after progression on ICI therapy between 2007 and 2017. The patients’ median age at the start of chemotherapy was 59 years. Most patients (60%) were men, 15% had BRAF V600 mutations, 86% had stage M1c disease, and 29% had brain metastases.